Behind generic drug shortages, House committee points to lackluster manufacturing and high prices
The seesaw between questionable generic drug manufacturing and rock bottom prices took the spotlight at a House Ways and Means Committee hearing on chronic drug shortages Tuesday morning.
“Poor manufacturing quality is the leading driver of chronic shortages and it’s the most preventable,” Committee Chair Jason Smith (R-MO) said at the start of the hearing. The committee turned to six experts from industry and academia to understand potential solutions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.